Schedule Update - effective 1 January 2011 (text extract)

This is the text extract for Schedule Update - effective 1 January 2011, browse documents here.

Pharmaceutical Management Agency

Update

New Zealand Pharmaceutical Schedule

Effective 1 January 2011

Section H cumulative for December 2010 and January 2011

Contents

Summary of PHARMAC decisions effective 1 January 2011 ........................... 3 Pharmacy Brand Switch payments ................................................................ 5 Nicotine – change to dispensing rules ........................................................... 5 Removal of Section 29 status ........................................................................ 6 Tretinoin – change of restriction.................................................................... 6 Apo-Clopidogrel tablets ................................................................................ 6 Moxifloxacin - removal of patient co-payment .............................................. 6 Tender News .................................................................................................. 7 Looking Forward ........................................................................................... 7 Sole Subsidised Supply products cumulative to January 2011 ....................... 8 New Listings ................................................................................................ 17 Changes to Restrictions ............................................................................... 19 Changes to Subsidy and Manufacturer’s Price............................................. 26 Changes to Sole Subsidised Supply ............................................................. 26 Delisted Items ............................................................................................. 27 Items to be Delisted .................................................................................... 30 Section H changes to Part II ........................................................................ 31 Index ........................................................................................................... 35

Summary of PharmaC decisions

effeCtive 1 jaNuary 2011 New listings (pages 17-18) • Lactulose (Laevolac) oral liq 10 g per 15 ml, 1,000 ml – Only on a prescription • Sodium chloride (Multichem) inj 0.9%, 5 ml and 10 ml – Up to 5 inj available on a PSO • Influenza vaccine (Fluvax, Fluarix) inj – Hospital pharmacy [Xpharm] • Nicotine (Habitrol) gum (classic) 2 mg and 4 mg, 96 pack – Nicotine will not be funded Close Control in amounts less than 4 weeks of treatment • Pharmacy Services (BSF Imuprine, BSF Dapa-Tabs, BSF Univent, and BSF Arrow Terazosin) brand switch fee – no patient co-payment payable – may only be claimed once per patient per fee Changes to restrictions (pages 19-25) • Terazosin hydrochloride (Arrow) tab 1 mg, 2 mg and 5 mg – a brand switch fee may be dispensed from 1 January 2011 until 31 March 2011 • Indapamide (Dapa-Tabs) tab 2.5 mg – a brand switch fee may be dispensed from 1 January 2011 until 31 March 2011 • Moxifloxacin (Avelox) tab 400 mg – No patient co-payment payable • Dapsone (Dapsone) tab 25 mg and 100 mg – removal of Section 29 • Bromocriptine mesylate (Apo-Bromocriptine) cap 5 mg – removal of Section 29 • Gabapentin (Nupentin) cap 100 mg, 300 mg and 400 mg – amended Special Authority criteria • Vigabatrin (Sabril) tab 500 mg – amended Special Authority criteria • Dexamphetamine sulphate (PSM) tab 5 mg – amended Special Authority criteria • Methylphenidate hydrochloride tab immediate-release 5 mg (Rubifen), tab immediate-release 10 mg (Ritalin, Rubifen), tab immediate-release 20 mg (Rubifen), and tab sustained-release 20 mg (Rubifen SR, Ritalin SR) – amended Special Authority criteria • Nicotine (Habitrol) gum (fruit, mint) 2 mg and 4 mg, lozenge 1 mg and 2 mg, patch 7 mg, 14 mg and 21 mg – removal of Original Pack (OP) – removal of all dispensing rules that currently apply (with the exception of the rule that Nicotine will not be funded Close Control in amounts less than 4 weeks, which will be retained) • Mitomycin C (Arrow) inj 5 mg – removal of Section 29 • Tretinoin (Vesanoid) cap 10 mg – addition of PCT – Retail pharmacy-Specialist • Azathioprine (Imuprine) tab 50 mg – a brand switch fee may be dispensed from 1 January 2011 until 31 March 2011 • Ipratropium bromide (Univent) nebuliser soln, 250 µg per ml, 1 ml and 2 ml – a brand switch fee may be dispensed from 1 January 2011 until 31 March 2011

Summary of PharmaC decisions – effective 1 january 2011 (continued) • Dermatological bases – removal of glycerol with paraffin and cetyl alcohol lotion, oily cream, and zinc cream BP from subsidised list Decreased subsidy (page 26) • Vitamins (Healtheries Multi-vitamin tablets) tab (BPC cap strength) • Captopril (Apo-Captopril) tab 12.5 mg, 25 mg and 50 mg • Raltegravir potassium (Isentress) tab 400 mg increased subsidy (page 26) • Methotrexate (Baxter) inj 1 mg for ECP

Pharmaceutical Schedule - Update News

Pharmacy Brand Switch payments

Brand switch payments for pharmacies will be payable for dispensings of terazosin hydrochloride tablets, indapamide tablets, azathioprine tablets and iptratropium bromide nebuliser solution from 1 January 2011. The brand switch fee is claimable via a Pharmacode on the first dispensing of each eligible pharmaceutical after 1 January 2011 for patients who have switched brands. Pharmacies should claim a fee even if the patient switched to the Sole Supply brand prior to 1 January 2011. The brand switch fees for each medicine will be paid only once for each patient during the claim period.

The brand switch fee will not be able to be claimed for these medicines for dispensing after 31 March 2011. Brand switch posters, leaflets and prescription bags are available free of charge. To order please go to www. pharmaconline.co.nz

Nicotine – change to dispensing rules

The listing of Habitrol larger pack sizes of lozenge 1 mg and 2 mg (216 pack) and patch 7 mg, 14 mg and 21 mg (28 pack) has been delayed due to stock unavailability. We will notify the market of the listing date when stock becomes available. This is expected to be a few months away. A new flavour of Habitrol nicotine gum, “classic”, will be subsidised from 1 January 2011. All formulations, strengths and pack sizes of nicotine replacement therapy (NRT) will be subject to the following rule from 1 January 2011: “Nicotine will not be funded Close Control in amounts less than 4 weeks of treatment”. All other prescribing and dispensing restrictions for NRT will be removed from 1 January 2011 and monthly dispensing will apply thereafter. NRT will no longer be subsidised as an Original Pack (OP).

Pharmaceutical Schedule - Update News

Removal of Section 29 status

A number of pharmaceuticals have recently been granted Ministerial Approval and no longer need to be supplied under Section 29 of the Medicines Act 1981. They are: • Link Pharmaceutical’s brand of dapsone tablets 25 mg and 100 mg; • Apotex’s Apo-Bromocriptine capsules 5 mg; and • Arrow Pharmaceutical’s mitomycin C injection 5 mg.

Tretinoin – change of restriction

From 1 January 2011, tretinoin caps 10 mg (Vesanoid) will have a “PCT – Retail pharmacy– Specialist” restriction. This means that it can be claimed by DHB hospitals when used for cancer treatment. When dispensed from a community pharmacy it will only be subsidised if it is prescribed by, or on the recommendation of, a specialist.

Apo-Clopidogrel tablets

The effective date of the delisting of Apo-Clopidogrel 75 mg tablets, 28 tablet pack only, has been revoked. Previously the 28 tablet pack had been notified as being delisted on 1 February 2011. Both the 90 and 28 tablet packs are currently fully subsidised at the same price and subsidy per tablet. The 28 tablet pack will be delisted once supplies are exhausted. The Apo-Clopidogrel brand of clopidogrel 75 mg tablets will be the Sole Subsidised Supply brand from 1 February 2011.

Moxifloxacin - removal of patient co-payment

From 1 January 2011 the patient co-payment will be removed for all subsidised prescriptions of moxifloxacin 400 mg tablets. This is to allow patients who receive moxifloxacin for the treatment of tuberculosis to continue to access their medication free of charge. However patients who take moxifloxacin 400 mg tablets for purposes other than tuberculosis will also be exempt from the co-payment. Also from this date moxifloxacin 400 mg tablets will not be eligible for the count towards the Prescription Subsidy Card.

tender News

Sole Subsidised Supply changes – effective 1 February 2011

Chemical Name Ceftriaxone sodium Clopidogrel Furosemide Mucilaginous laxatives Sodium cromoglycate Vitamin B complex Presentation; Pack size Inj 500 mg; 1 inj Tab 75 mg; 90 tab Inj 10 mg per ml, 2 ml; 5 inj Dry, 500 g OP Eye drops 2%; 5 ml OP Tab, strong, BPC; 500 tab Sole Subsidised Supply brand (and supplier) Veracol (Multichem) Apo-Clopidogrel (Apotex) Frusemide-Claris (AFT) Konsyl-D (Mylan) Rexacrom (Rex Medical) B-PlexADE (Boucher & Muir)

Looking forward

This section is designed to alert both pharmacists and prescribers to possible future changes to the Pharmaceutical Schedule. It may also assist pharmacists, distributors and wholesalers to manage stock levels. Possible decisions for implementation 1 february 2011 • Brand Switch Fees – captopril tab, clopidogrel tab, and cilazapril tab • Caffeine citrate (Biomed) oral liq 20 mg per ml (10 mg base per ml), 25 ml OP – new listing • Ezetimibe (Ezetrol) tab 10 mg – price and subsidy decrease • Ezetimibe with simvastatin (Vytorin) tab 10 mg with simvastatin 10 mg, 20 mg, 40 mg and 80 mg – price and subsidy decrease • Fentanyl (Mylan Fentanyl Patch) transdermal patch 12.5 µg per hour, 25 µg per hour, 50 µg per hour, 75 µg per hour and 100 µg per hour – new listing, Special Authority not required • Fentanyl (Durogesic) transdermal patch 25 µg per hour, 50 µg per hour, 75 µg per hour and 100 µg per hour – amend Special Authority criteria so that only existing patients can continue with subsidy. • Potassium citrate (Biomed) oral liq 3 mmol per ml, 200 ml OP – new listing with Special Authority criteria • Salbutamol with ipratropium bromide (Duolin HFA) aerosol inhaler 100 µg with ipratropium bromide 20 µg per dose, 200 dose OP – new listing • Sodium chloride (Biomed) soln 7%, 90 ml OP – new listing

Sole Subsidised Supply Products – cumulative to January 2011

Generic Name

Acarbose Acetazolamide Aciclovir Allopurinol Amantadine hydrochloride Amlodipine Amoxycillin

Presentation

Tab 50 mg & 100 mg Tab 250 mg Tab dispersible 200 mg, 400 mg & 800 mg Tab 100 mg & 300 mg Cap 100 mg Tab 5 mg & 10 mg Grans for oral liq 250 mg per 5 ml Drops 125 mg per 1.25 ml Inj 250 mg, 500 mg & 1 g

Brand Name Expiry Date*

Glucobay Diamox Lovir Apo-Allopurinol Symmetrel Apo-Amlodipine Ospamox Ospamox Paediatric Drops Ibiamox Curam Curam Synermox AFT Vitala-C Ethics Aspirin EC Ethics Aspirin Atenolol Tablet USP AstraZeneca Imuprine Imuran Arrow-Azithromycin Pacifen ArrowBendrofluazide Sandoz Beta Scalp Fibalip Bicalox Lax-Tab AFT healthE API Miacalcic 2011 2011 2013 2013 2012 2012 2013 2012 2012 2011 2011 2012 2011 2011 2013 2011 2012 2011 2012 2011 2013 2011 2011 2011 2012 2011

Amoxycillin clavulanate

Grans for oral liq amoxycillin 125 mg with potassium clavulanate 31.25 mg per 5 ml Grans for oral liq amoxycillin 250 mg with potassium clavulanate 62.5 mg per 5 ml Tab amoxycillin 500 mg with potassium clavulanate 125 mg Crm 500 g Tab 100 mg Tab 100 mg Tab dispersible 300 mg Tab 50 mg & 100 mg Inj 600 µg, 1 ml Tab 50 mg Inj 50 mg Tab 500 mg Tab 10 mg Tab 2.5 mg & 5 mg Inj 1 mega u Scalp app 0.1% Tab 200 mg Tab 50 mg Tab 5 mg Eye drops 0.2% Crm, aqueous, BP Lotn, BP Inj 100 iu per ml, 1 ml

2012

Aqueous cream Ascorbic acid Aspirin Atenolol Atropine sulphate Azathioprine Azithromycin Baclofen Bendrofluazide Benzylpenicillin sodium (Penicillin G) Betamethasone valerate Bezafibrate Bicalutamide Bisacodyl Brimonidine tartrate Calamine Calcitonin

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply Products – cumulative to January 2011

Generic Name

Calcitriol Calcium carbonate

Presentation

Cap 0.25 µg & 0.5 µg Tab 1.25 g (500 mg elemental) Tab 1.5 g (600 mg elemental) Tab eff 1.7 g (1 g elemental) Inj 50 mg Oral liq 5 mg per ml Grans for oral liq 125 mg per 5 ml Inj 500 mg & 1 g Inj 1 g Inj 750 mg & 1.5 g Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Tab 10 mg Oral liq 1 mg per ml Crm BP Eye oint 1% Handrub 1% with ethanol 70% Soln 4% Nail soln 8% Tab 5 mg with hydrochlorothiazide 12.5 mg Tab 250 mg, 500 mg & 750 mg Tab 20 mg Crm 0.05% Oint 0.05% Scalp app 0.05% Tab 500 µg & 2 mg TDDS 2.5 mg, 100 µg per day TDDS 5 mg, 200 µg per day TDDS 7.5 mg, 300 µg per day Inj 150 µg per ml, 1 ml Tab 25 µg Tab 150 µg Vaginal crm 1% with applicator Vaginal crm 2% with applicator Crm 1% Soln BP Tab 500 µg Crm 10%

Brand Name Expiry Date*

Airflow Calci-Tab 500 Calci-Tab 600 Calsource Calcium Folinate Ebewe Capoten Ranbaxy-Cefaclor Hospira Aspen Ceftriaxone Zinacef Cefalexin Sandoz Cefalexin Sandoz Zetop Cetirizine-AFT PSM Chlorsig healthE Orion Batrafen Inhibace Plus Rex Medical Arrow-Citalopram Dermol Dermol Dermol Paxam Catapres-TTS-1 Catapres-TTS-2 Catapres-TTS-3 Catapres Dixarit Catapres Clomazol Clomazol Clomazol Midwest Colgout Itch-Soothe 2012 2011

Calcium folinate Captopril Cefaclor monohydrate Cefazolin sodium Ceftriaxone sodium Cefuroxime sodium Cephalexin monohydrate Cetirizine hydrochloride Cetomacrogol Chloramphenicol Chlorhexidine gluconate Ciclopiroxolamine Cilazapril with hydrochlorothiazide Ciprofloxacin Citalopram Clobetasol propionate

2011 2013 2013 2011 2013 2011 2012 2011 2013 2012 2012 2011 2012 2013 2011 2011 2012

Clonazepam Clonidine

2011 2012

Clonidine hydrochloride

2012

Clotrimazole

2013 2011 2013 2013 2012

Coal tar Colchicine Crotamiton

Sole Subsidised Supply Products – cumulative to January 2011

Generic Name

Cyclizine hydrochloride Cyclophosphamide Cyproterone acetate Cyproterone acetate with ethinyloestradiol Desmopressin Dexamethasone Dexamethasone sodium phosphate Dextrose Dextrose with electrolytes

Presentation

Tab 50 mg Tab 50 mg Tab 50 mg & 100 mg Tab 2 mg with ethinyloestradiol 35 µg and 7 inert tabs Nasal spray 10 µg per dose Eye drops 0.1% Inj 4 mg per ml, 1 ml & 2 ml Inj 50%, 10 ml Soln with electrolytes

Brand Name Expiry Date*

Nausicalm Cycloblastin Siterone Ginet 84 Desmopressin-PH&T Maxidex Hospira Biomed Pedialyte – Fruit Pedialyte – Bubblegum Pedialyte – Plain Diclofenac Sandoz Voltaren Ophtha Voltaren Voltaren DHC Continus Dilzem Cardizem CD Pytazen SR Laxofast 50 Laxofast 120 Laxsol Donepezil-Rex AFT Arrow-Enalapril Clexane Comtan E-Mycin E-Mycin E-Mycin NZ Medical and Scientific Arrow-Etidronate Felo 5 ER Felo 10 ER 2012 2013 2012 2011 2011 2013 2013 2011 2013

Diclofenac sodium

Tab EC 25 mg & 50 mg Eye drops 1 mg per ml Inj 25 mg per ml, 3 ml Suppos 12.5 mg, 25 mg, 50 mg & 100 mg Tab long-acting 60 mg Tab 30 mg & 60 mg Cap long-acting 120 mg, 180 mg & 240 mg Tab long-acting 150 mg Cap 50 mg Cap 120 mg Tab 50 mg with total sennosides 8 mg Tab 5 mg & 10 mg Oint BP Tab 5 mg, 10 mg & 20 mg Inj 20 mg, 40 mg, 60 mg, 80 mg, 100 mg, 120 mg & 150 mg Tab 200 mg Tab 400 mg Grans for oral liq 200 mg per 5 ml Grans for oral liq 400 mg per 5 ml Tab 10 µg Tab 200 mg Tab long-acting 5 mg Tab long-acting 10 mg

2012 2011

Dihydrocodeine tartrate Diltiazem hydrochloride

2013 31/12/11

Dipyridamole Docusate sodium Docusate sodium with sennosides Donepezil hydrochloride Emulsifying ointment Enalapril Enoxaparin sodium (low molecular weight heparin) Entacapone Erythromycin ethyl succinate

2011 2011 2013 2012 2011 2012 2012 2012 2012 2011 2012 2012 2012

Ethinyloestradiol Etidronate disodium Felodipine

Sole Subsidised Supply Products – cumulative to January 2011

Generic Name

Ferrous sulphate Finasteride Flucloxacillin sodium

Presentation

Oral liq 30 mg per 1 ml (6 mg elemental per 1 ml) Tab 5 mg Cap 250 mg & 500 mg Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Inj 250 mg, 500 mg & 1 g Cap 50 mg, 150 mg & 200 mg Inj 50 mg Tab 10 mg Eye drops 0.1% Cap 20 mg Tab dispersible 20 mg, scored Tab 250 mg Metered aqueous nasal spray, 50 µg per dose Tab 40 mg Crm 2% Oint 2% Cap 100 mg, 300 mg & 400 mg Inj 40 mg per ml, 2 ml Tab 80 mg Tab 5 mg Liquid Tab 600 µg Oral pump spray 400 µg per dose TDDS 5 mg & 10 mg

Brand Name Expiry Date*

Ferodan Fintral AFT AFT AFT Flucloxin Pacific Fludara Fludara Oral FML Fluox Fluox Flutamin Flixonase Hayfever & Allergy Diurin 40 Foban Foban Nupentin Pfizer Apo-Gliclazide Minidiab healthE Lycinate Nitrolingual Pumpspray Nitroderm TTS Serenace Serenace Serenace Solu-Cortef Douglas ABM PSM Colifoam Micreme H DP Lotn HC 2013 2011 2012 2011 2011 2011 2012 2013 2013 31/1/13 2012 2013 31/7/12 2012 2011 2011 2013 2011

Fluconazole Fludarabine phosphate Fluorometholone Fluoxetine hydrochloride Flutamide Fluticasone propionate Furosemide Fusidic acid Gabapentin Gentamicin sulphate Gliclazide Glipizide Glycerol Glyceryl trinitrate

Haloperidol

Inj 5 mg per ml, 1 ml Oral liq 2 mg per ml Tab 500 µg, 1.5 mg & 5 mg Inj 50 mg per ml, 1 ml Tab 5 mg & 20 mg Powder Crm 1%, 500 g Rectal foam 10%, CFC-free (14 applications) Crm 1% with miconazole nitrate 2% Lotn 1% with wool fat hydrous 3% and mineral oil

2013

Hydrocortisone

2013 2012 2011 2012 2013 2011

Hydrocortisone acetate Hydrocortisone with miconazole Hydrocortisone with wool fat and mineral oil

Sole Subsidised Supply Products – cumulative to January 2011

Generic Name

Hydroxocobalamin Hydroxychloroquine sulphate Hypromellose Hysocine N-butylbromide Ibuprofen Indapamide Ipratropium bromide Iron polymaltose Isotretinoin Ketoconazole Lamivudine Latanoprost Letrozole Levonorgestrel Lignocaine hydrochloride Lignocaine with prilocaine

Presentation

Inj 1 mg per ml, 1 ml Tab 200 mg Eye drops 0.5% Inj 20 mg, 1 ml Tab 20 mg Oral liq 100 mg per 5 ml Tab 200 mg Tab 2.5 mg Nebuliser soln, 250 µg per ml, 1 ml & 2 ml Inj 50 mg per ml, 2 ml Cap 10 mg & 20 mg Shampoo 2% Oral liq 10 mg per ml Tab 150 mg Eye drops 50 µg per ml Tab 2.5 mg Subdermal implant (2 x 75 mg rods) Inj 1%, 5 ml & 20 ml Crm 2.5% with prilocaine 2.5% (5 g tubes) Crm 2.5% with prilocaine 2.5%; 30 g OP Tab 5 mg, 10 mg & 20 mg Oral liq 1 mg per ml Tab 10 mg Tab 1 mg & 2.5 mg Liq 0.5% Shampoo 1% Device Tab 100 mg Tab 135 mg Tab 160 mg Tab 50 mg Enema 1 g per 100 ml Tab immediate-release 500 mg & 850 mg

Brand Name Expiry Date*

ABM Hydroxocobalamin Plaquenil Methopt Buscopan Gastrosoothe Fenpaed Ethics Ibuprofen Dapa-Tabs Univent Ferrum H Oratane Sebizole 3TC 3TC Hysite Letara Jadelle Xylocaine EMLA EMLA Arrow-Lisinopril Lorapaed Loraclear Hayfever Relief Ativan A-Lices A-Lices Foremount Child’s Silicone Mask De-Worm Colofac Apo-Megestrol Purinethol Pentasa Apotex 2012 2013 2012 2012 2011 2011 2013 2012 2013 2013 2011 2012 2011 2013 2012 2012 31/12/13 2013 2013

Lisinopril Loratadine

Lorazepam Malathion Mask for Spacer Device Mebendazole Mebeverine hydrochloride Megestrol acetate Mercaptopurine Mesalazine Metformin hydrochloride

2013 2013 30/9/11 2011 2011 2012 2013 2012 2012

Sole Subsidised Supply Products – cumulative to January 2011

Generic Name

Methadone hydrochloride

Presentation

Tab 5 mg Oral liq 2 mg per ml Oral liq 5 mg per ml Oral liq 10 mg per ml Inj 25 mg per ml, 2 ml & 20 ml Tab 2.5 mg & 10 mg Inj 100 mg per ml, 10 ml & 50 ml Tab 125 mg, 250 mg & 500 mg Tab 4 mg & 100 mg Inj 40 mg per ml, 1 ml Inj 40 mg per ml with lignocaine 1 ml Inj 40 mg per ml, 1 ml Inj 62.5 mg per ml, 2 ml Inj 500 mg Inj 1 g Inj 5 mg per ml, 2 ml Crm 2% Tab 150 mg & 300 mg Crm 0.1% Oint 0.1% Oral liq 1 mg per ml Oral liq 2 mg per ml Oral liq 5 mg per ml Oral liq 10 mg per ml Cap long-acting 10 mg, 30 mg, 60 mg & 100 mg Tab immediate release 10 mg & 20 mg Inj 10 mg per ml, 1 ml Inj 30 mg per ml, 1 ml Inj 80 mg per ml, 1.5 ml & 5 ml Tab 250 mg Tab 500 mg Oral suspension 10 mg per ml Tab 200 mg

Brand Name Expiry Date*

Methatabs Biodone Biodone Forte Biodone Extra Forte Hospira Methoblastin Methotrexate Ebewe Prodopa Medrol Depo-Medrol Depo-Medrol with Lidocaine Solu-Medrol Solu-Medrol Solu-Medrol Solu-Medrol Pfizer Multichem Apo-Moclobemide m-Mometasone m-Mometasone RA-Morph RA-Morph RA-Morph RA-Morph m-Elson Sevredol Mayne Mayne Hospira Noflam 250 Noflam 500 Viramune Suspension Viramune Noriday 28 Primolut N Norpress Nilstat Nilstat Nilstat 2013 2012

Methotrexate

2013 2012 2011 2011 2012 2011 2011 2012

Methyldopa Methylprednisolone Methylprednisolone acetate Methylprednisolone acetate with lignocaine Methylprednisolone sodium succinate

Metoclopramide hydrochloride Miconazole nitrate Moclobemide Mometasone furoate Morphine hydrochloride

2011 2011 2012 2012 2012

Morphine sulphate

2013 2012 2011 2013 2012 2012

Morphine tartrate Naproxen Nevirapine

Norethisterone Nortriptyline hydrochloride Nystatin

Tab 350 µg Tab 5 mg Tab 10 mg & 25 mg Cap 500,000 u Tab 500,000 u Oral liq 100,000 u per ml, 24 ml OP

2012 2011 2011 2013 2011

Sole Subsidised Supply Products – cumulative to January 2011

Generic Name

Omeprazole

Presentation

Cap 10 mg, 20 mg & 40 mg Inj 40 mg

Brand Name Expiry Date*

Dr Reddy’s Omeprazole Dr Reddy’s Omeprazole Syntocinon Syntocinon Syntometrine Pamisol Pamisol Pamisol Dr Reddy’s Pantoprazole Pharmacare Paracare Junior Paracare Double Strength ParaCode Lacri-Lube Loxamine Breath-Alert Pegasys Pegasys Pegasys RBV Combination Pack Pegasys RBV Combination Pack Pegasys RBV Combination Pack Pegasys RBV Combination Pack Permax A-Scabies Cilicaine VK AFT AFT Apo-Pindolol Pizaccord Sandomigran Coloxyl Vistil Vistil Forte 2012 2012 2012 2011 2011 2011

Oxytocin

Inj 5 iu per ml, 1 ml Inj 10 iu per ml, 1 ml Inj 5 iu with ergometrine maleate 500 µg per ml, 1 ml Inj 3 mg per ml, 5 ml Inj 3 mg per ml, 10 ml Inj 6 mg per ml, 10 ml Tab 20 mg & 40 mg Tab 500 mg Oral liq 120 mg per 5 ml Oral liq 250 mg per 5 ml Tab paracetamol 500 mg with codeine phosphate 8 mg Eye oint with soft white paraffin Tab 20 mg Low range and Normal range Inj 135 µg prefilled syringe Inj 180 µg prefilled syringe Inj 135 µg prefilled syringe x 4 with ribavirin tab 200 mg x 112 Inj 135 µg prefilled syringe x 4 with ribavirin tab 200 mg x 168 Inj 180 µg prefilled syringe x 4 with ribavirin tab 200 mg x 112 Inj 180 µg prefilled syringe x 4 with ribavirin tab 200 mg x 168 Tab 0.25 mg & 1 mg Lotn 5% Cap potassium salt 250 mg & 500 mg Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Tab 5 mg, 10 mg & 15 mg Tab 15 mg, 30 mg & 45 mg Tab 500 µg Oral drops 10% Eye drops 1.4% Eye drops 3%

2012

Pamidronate disodium

2011

Pantoprazole Paracetamol

2013 2011

Paracetamol with codeine Paraffin liquid with soft white paraffin Paroxetine hydrochloride Peak Flow Meter Pegylated interferon alpha-2A

2011 2013 2013 30/9/11 31/12/12

Pergolide Permethrin Phenoxymethylpenicillin (Pencillin V)

2011 2011 2013

Pindolol Pioglitazone Pizotifen Poloxamer Polyvinyl alcohol

Sole Subsidised Supply Products – cumulative to January 2011

Generic Name

Potassium chloride Prednisone Prednisone sodium phosphate Pregnancy tests – hCG urine Procaine penicillin Promethazine hydrochloride

Presentation

Tab long-acting 600 mg Tab 1 mg, 2.5 mg, 5 mg & 20 mg Oral liq 5 mg per ml Cassette Inj 1.5 mega u Oral liq 5 mg per 5 ml Tab 10 mg & 25 mg

Brand Name Expiry Date*

Span-K Apo-Prednisone Redipred Innovacon hCG One Step Pregnancy Test Cilicaine Promethazine Winthrop Elixir Allersoothe Accupril Accuretic 10 Accuretic 20 Q 300 Mycobutin Ropin ArrowRoxithromycin Salapin Asthalin Asthalin Duolin 2012 2013 2013 2012 2013 2012 2012 2012 2011 2012 2012 2011 2012 2011 2011 2011

Quinapril Quinapril with hydrochlorothiazide

Tab 5 mg, 10 mg & 20 mg Tab 10 mg with hydrochlorothiazide 12.5 mg Tab 20 mg with hydrochlorothiazide 12.5 mg Tab 300 mg Cap 150 mg Tab 0.25 mg, 1 mg, 2 mg & 5 mg Tab 150 mg & 300 mg Oral liq 2 mg per 5 ml Nebuliser soln, 1 mg per ml, 2.5 ml Nebuliser soln, 2 mg per ml, 2.5 ml Nebuliser soln, 2.5 mg with ipratopium bromide 0.5 mg per vial, 2.5 ml Tab 5 mg Tab 10 mg Tab 20 mg Tab 40 mg Tab 80 mg Inj 23.4%, 20 ml Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml Grans effervescent 4 g sachets Nasal spray, 4% Inj cartridge 16 iu (5.3 mg) Inj cartridge 36 iu (12 mg) Tab 80 mg & 160 mg 230 ml, autoclavable & single patient Tab 25 mg & 100 mg Tab 50 mg & 100 mg

Quinine sulphate Rifabutin Ropinirole hydrochloride Roxithromycin Salbutamol

Salbutamol with ipratropium bromide Selegiline hydrochloride Simvastatin

Apo-Selegiline Arrow-Simva 10 mg Arrow-Simva 20 mg Arrow-Simva 40 mg Arrow-Simva 80 mg Biomed Micolette Ural Rex Genotropin Genotropin Mylan Space Chamber Spirotone Arrow-Sumatriptan

2012 2011

Sodium chloride Sodium citrate with sodium lauryl sulphoacetate Sodium citro-tartrate Sodium cromoglycate Somatropin Sotalol Spacer Device Spironolactone Sumatriptan

2013 2013 2013 2012 31/12/12 2012 30/9/11 2013 2013

Sole Subsidised Supply Products – cumulative to January 2011

Generic Name

Tamsulosin hydrochloride Tar with triethanolamine lauryl sulphate and fluorescein Temazepam Terazosin hydrochloride Terbinafine Testosterone cypionate Testosterone undecanoate Tetracosactrin Timolol maleate Tramadol hydrochloride Tranexamic acid Triamcinolone acetonide

Presentation

Cap 400 µg Soln 2.3% Tab 10 mg Tab 1 mg, 2 mg & 5 mg Tab 250 mg Inj long-acting 100 mg per ml, 10 ml Cap 40 mg Inj 250 µg Inj 1 mg per ml, 1 ml Tab 10 mg Eye drops 0.25% & 0.5% Cap 50 mg Tab 500 mg Crm 0.02% Oint 0.02% Inj 40 mg per ml, 1 ml 0.1% in Dental Paste USP Tab 300 mg Cap 5 mg Cap 300 mg Inj 50 mg per ml, 10 ml Cap 100 mg Oral liq 10 mg per ml Oint BP Cap 137.4 mg (50 mg elemental) Tab 7.5 mg

Brand Name Expiry Date*

Tamsulosin-Rex Pinetarsol Normison Arrow Apo-Terbinafine Depo-Testosterone Arrow-Testosterone Synacthen Synacthen Depot Apo-Timol Apo-Timop Arrow-Tramadol Cycklokapron Aristocort Aristocort Kenacort-A40 Oracort TMP Navoban Actigall Pacific Retrovir Retrovir PSM Zincaps Apo-Zopiclone 2013 2011 2011 2013 2011 2011 2012 2011 2012 2011 2011 2013 2011

Trimethoprim Tropisetron Ursodeoxycholic acid Vancomycin hydrochloride Zidovudine [AZT] Zinc and castor oil Zinc sulphate Zopiclone January changes in bold

2011 2012 2011 2011 2013 2011 2011 2011

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New Listings

Effective 1 January 2011

34 43 LACTULOSE – Only on a prescription ❋ Oral liq 10 g per 15 ml .............................................................. 7.68 SODIUM CHLORIDE Inj 0.9%, 5 ml – Up to 5 inj available on a PSO ......................... 10.85 Inj 0.9%, 10 ml – Up to 5 inj available on a PSO ....................... 11.50 1,000 ml 50 50 ✔ Laevolac ✔ Multichem ✔ Multichem

INFLUENZA VACCINE – Hospital pharmacy [Xpharm] A) is available 1 March until vaccine supplies are exhausted each year for patients who meet the following criteria, as set by the Ministry of Health: a) all people 65 years of age and over; b) people under 65 years of age with: i) the following cardiovascular disease: 1) ischaemic heart disease, 2) congestive heart disease, 3) rheumatic heart disease, 4) congenital heart disease, or 5) cerebo-vascular disease; ii) the following chronic respiratory disease: 1) asthma, if on a regular preventative therapy, or 2) other chronic respiratory disease with impaired lung function; iii)diabetes; iv) chronic renal disease; v) any cancer, excluding basal and squamous skin cancers if not invasive; vi) the following other conditions: a) autoimmune disease, b) immune suppression, c) HIV, d) transplant recipients, e) neuromuscular and CNS diseases, f) haemoglobinopathies, or g) children on long term aspirin. c) people under 65 years of age who are: i) pregnant; or ii) morbidly obsese d) children aged over 6 months and under 5 years who are from high deprivation backgrounds The following conditions are excluded from funding: a) asthma not requiring regular preventative therapy, b) hypertension and/or dyslipidaemia without evidence of end-organ disease, B) Doctors are the only Contractors entitled to claim payment from the Funder for the supply of influenza vaccine to patients eligible under the above criteria for subsidised immunisation and they may only do so in respect of the influenza vaccine listed in the Pharmaceutical Schedule. C) Individual DHBs may fund patients over and above the above criteria. The claiming process for these additional patients should be determined between the DHB and Contractor. D) Influenza Vaccine does not fall within the definition Community Pharmaceutical as it is not funded directly from the Pharmaceutical Budget. Pharmacists are unable to claim for the dispensing of influenza vaccine from the Funder. Inj .......................................................................................... 90.00 10 ✔ Fluvax ✔ Fluarix

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New listings - effective 1 January 2011 (continued)

142 NICOTINE Nicotine will not be funded Close Control in amounts less than 4 weeks of treatment. Gum 2 mg (Classic) ............................................................... 14.97 96 Gum 4 mg (Classic) ............................................................... 20.02 96 PHARMACY SERVICES – May only be claimed once per patient. ❋ Brand switch fee........................................................................ 0.01 The Pharmacode for BSF Imuprine is 2377829 ❋ Brand switch fee........................................................................ 0.01 The Pharmacode for BSF Dapa-Tabs is 2377837 ❋ Brand switch fee........................................................................ 0.01 The Pharmacode for BSF Univent is 2377845 ❋ Brand switch fee........................................................................ 0.01 The Pharmacode for BSF Arrow Terazosin is 2377853 (BSF Imuprine to be delisted 1 April 2011) (BSF Dapa-Tabs to be delisted 1 April 2011) (BSF Univent to be delisted 1 April 2011) (BSF Arrow Terazosin to be delisted 1 April 2011) 1 fee 1 fee 1 fee 1 fee

✔ Habitrol ✔ Habitrol ✔ BSF Imuprine ✔ BSF Dapa-Tabs ✔ BSF Univent ✔ BSF Arrow Terazosin

171

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions

Effective 1 January 2011

47 TERAZOSIN HYDROCHLORIDE – Brand switch fee payable ❋ Tab 1 mg ................................................................................. 1.50 ❋ Tab 2 mg ................................................................................. 0.80 ❋ Tab 5 mg ................................................................................. 1.00 INDAPAMIDE – Brand switch fee payable ❋ Tab 2.5 mg .............................................................................. 2.95 28 28 28 90 ✔ Arrow ✔ Arrow ✔ Arrow ✔ Dapa-Tabs

54 86

MOXIFLOXACIN – Special Authority see SA1065 – Retail pharmacy – No patient co-payment payable Tab 400 mg ........................................................................... 52.00 5 ✔ Avelox ➽ SA1065 Special Authority for Subsidy Initial application only from a respiratory specialist or infectious disease specialist. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 Both: 1.1 Active tuberculosis*; and 1.2 Any of the following: 1.2.1 Documented resistance to one or more first-line medications; or 1.2.2 Suspected resistance to one or more first-line medications (tuberculosis assumed to be contracted in an area with known resistance), as part of regimen containing other second-line agents; or 1.2.3 Impaired visual acuity (considered to preclude ethambutol use); or 1.2.4 Significant pre-existing liver disease or hepatotoxicity from tuberculosis medications; or 1.2.5 Significant documented intolerance and/or side effects following a reasonable trial of first-line medications; or 2 Mycobacterium avium-intracellulare complex not responding to other therapy or where such therapy is contraindicated.*. Note: Indications marked with * are Unapproved Indications (refer to Section A: General Rules, Part I (Interpretations and Definitions) and Part IV (Miscellaneous Provisions) rule 4.6). Renewal only from a respiratory specialist or infectious disease specialist. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment.

DAPSONE – No patient co-payment payable Tab 25 mg ............................................................................. 95.00 Tab 100 mg ......................................................................... 110.00 BROMOCRIPTINE MESYLATE ❋ Cap 5 mg ............................................................................... 60.43 GABAPENTIN – Special Authority see SA1071 1009– Retail pharmacy ▲ Cap 100 mg ............................................................................. 7.16 ▲ Cap 300 mg ........................................................................... 11.50 ▲ Cap 400 mg ........................................................................... 14.75

100 100 100

✔ Dapsone S29 ✔ Dapsone S29 ✔ Apo-Bromocriptine

S29

115

123

100 100 100

✔ Nupentin ✔ Nupentin ✔ Nupentin

➽ SA1071 1009 Special Authority for Subsidy Initial application — (Epilepsy - new patients) from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria: Either: 1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or continued...

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 January 2011 (continued)

continued... 2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents. Note: "Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient’s age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance. Initial application — (Epilepsy - patient has had an approval for gabapentin, lamotrigine, topiramate or vigabatrin for epilepsy prior to 1 August 2007) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life from gabapentin; or 2 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents, or seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents. Notes: "Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient’s age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance. As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient’s perspective. Initial application — (Neuropathic pain - new patients) from any relevant practitioner. Approvals valid for 3 months where the patient has tried and failed, or has been unable to tolerate, treatment with a tricyclic antidepressant. Initial application — (Neuropathic pain - patient has had an approval for gabapentin for neuropathic pain prior to 1 August 2007) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 The patient has demonstrated a marked improvement in their control of pain (prescriber determined); or 2 The patient has previously demonstrated clinical responsiveness to gabapentin and has now developed neuropathic pain in a new site. Renewal — (Epilepsy) from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life. Notes: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient’s perspective. If the patient had an approval for gabapentin, lamotrigine, topiramate or vigabatrin for epilepsy prior to 1 August 2007 the applicant is required to submit a fresh initial application in the first instance, not a renewal application. Renewal — (Neuropathic pain) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 The patient has demonstrated a marked improvement in their control of pain (prescriber determined); or 2 The patient has previously demonstrated clinical responsiveness to gabapentin and has now developed neuropathic pain in a new site. Note: If the patient had an approval for gabapentin for neuropathic pain prior to 1 August 2007 the applicant is required to submit a fresh initial application in the first instance, not a renewal application. 125 VIGABATRIN – Special Authority see SA1072 1010 – Retail pharmacy ▲ Tab 500 mg ......................................................................... 119.30 100 ✔ Sabril

➽ SA1072 1010 Special Authority for Subsidy Initial application — (new patients) from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria: continued... Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 January 2011 (continued)

continued... Both: 1 Either: 1.1 Patient has infantile spasms; or 1.2 Both: 1.2.1 Patient has epilepsy; and 1.2.2 Either: 1.2.2.1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or 1.2.2.2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents; and 2 Either: 2.1 Patient is, or will be, receiving regular automated visual field testing (ideally before starting therapy and on a 6-monthly basis thereafter); or 2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient’s visual fields. Notes: “Optimal treatment with other antiepilepsy agents” is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient’s age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance. Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages. Initial application — (patient has had an approval for gabapentin, lamotrigine, topiramate or vigabatrin for epilepsy prior to 1 August 2007) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either: 1 Patient is receiving regular automated visual field testing (ideally every 6 months) on an ongoing basis for the duration of treatment with vigabatrin; or 2 It is impractical or impossible (due to comorbid conditions) to monitor the patient’s visual fields. Note: Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages. Renewal from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 The patient has demonstrated a significant and sustained improvement in seizure rate or severity and or quality of life; and 2 Either: 2.1 Patient is receiving regular automated visual field testing (ideally every 6 months) on an ongoing basis for duration of treatment with vigabatrin; or 2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient’s visual fields. Notes: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient’s perspective. Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages. If the patient had an approval for gabapentin, lamotrigine, topiramate or vigabatrin for epilepsy prior to 1 August 2007 the applicant is required to submit a fresh initial application in the first instance, not a renewal application. 137 DEXAMPHETAMINE SULPHATE – Special Authority see SA1073 0907 – Retail pharmacy Only on a controlled drug form Tab 5 mg ............................................................................... 16.50 100 ✔ PSM ➽ SA1073 0907 Special Authority for Subsidy Initial application — (ADHD in patients 5 or over – new patients) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria: continued...

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 January 2011 (continued)

continued... All of the following: 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients aged 5 years or over; and 2 Diagnosed according to DSM-IV or ICD 10 criteria; and 3 Either: 3.1 Applicant is a paediatrician or psychiatrist; or 3.2 Both: 3.2.1 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient; and 3.2.2 Provide name of the recommending specialist. Initial application — (ADHD in patients 5 or over - patient has had an approval for dexamphetamine for ADHD prior to 1 April 2008) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 Applicant is a paediatrician or psychiatrist; or 2.2 Both: 2.2.1 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient; and 2.2.2 Provide name of the recommending specialist. Initial application — (ADHD in patients under 5 – new patients) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients under 5 years of age; and 2 Diagnosed according to DSM-IV or ICD 10 criteria. Initial application — (ADHD in patients under 5 - patient has had an approval for dexamphetamine for ADHD in patients under 5 prior to 1 April 2008) only from a paediatrician or psychiatrist. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment. Initial application —(Narcolepsy – new patients) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the patient suffers from narcolepsy. Initial application — (Narcolepsy - patient has had an approval for dexamphetamine for narcolepsy prior to 1 April 2008) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the treatment remains appropriate and the patient is benefiting from treatment. Renewal — (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 Applicant is a paediatrician or psychiatrist; or 2.2 Both: 2.2.1 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient; and 2.2.2 Provide name of the recommending specialist. Note: If the patient had an approval for dexamphetamine for ADHD prior to 1 April 2008 the applicant is required to submit a fresh initial application in the first instance, not a renewal application. Please phone the Contact Centre on 0800 243 666 for clarification if needed. Renewal — (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment. continued... Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

S29

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 January 2011 (continued)

continued... Note: If the patient had an approval for dexamphetamine for ADHD in patients under 5 prior to 1 April 2008 the applicant is required to submit a fresh initial application in the first instance, not a renewal application. Please phone the Contact Centre on 0800 243 666 for clarification if needed. Renewal — (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the treatment remains appropriate and the patient is benefiting from treatment. Note: If the patient had an approval for dexamphetamine for narcolepsy prior to 1 April 2008 the applicant is required to submit a fresh initial application in the first instance, not a renewal application. Please phone the Contact Centre on 0800 243 666 for clarification if needed. 138 METHYLPHENIDATE HYDROCHLORIDE – Special Authority see SA1074 0908 – Retail pharmacy Only on a controlled drug form Tab immediate-release 5 mg ..................................................... 3.20 30 ✔ Rubifen Tab immediate-release 10 mg ................................................... 3.00 30 ✔ Ritalin ✔ Rubifen Tab immediate-release 20 mg ................................................... 7.85 30 ✔ Rubifen Tab sustained-release 20 mg .................................................. 10.95 30 ✔ Rubifen SR 50.00 100 ✔ Ritalin SR ➽ SA1074 0908 Special Authority for Subsidy Initial application — (ADHD in patients 5 or over – new patients) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria: All of the following: 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients aged 5 years or over; and 2 Diagnosed according to DSM-IV or ICD 10 criteria; and 3 Either: 3.1 Applicant is a paediatrician or psychiatrist; or 3.2 Both: 3.2.1 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient; and 3.2.2 Provide name of the recommending specialist. Initial application — (ADHD in patients 5 or over - patient has had an approval for methylphenidate for ADHD prior to 1 April 2008) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 Applicant is a paediatrician or psychiatrist; or 2.2 Both: 2.2.1 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient; and 2.2.2 Provide name of the recommending specialist. Initial application — (ADHD in patients under 5 – new patients) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria: Both: 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients under 5 years of age; and 2 Diagnosed according to DSM-IV or ICD 10 criteria. Initial application — (ADHD in patients under 5 - patient has had an approval for methylphenidate for ADHD in patients under 5 prior to 1 April 2008) only from a paediatrician or psychiatrist. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment. Initial application — (Narcolepsy – new patients) only from a neurologist or respiratory specialist. Approvals valid continued... for 24 months where the patient suffers from narcolepsy.

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 January 2011 (continued)

continued... Initial application — (Narcolepsy - patient has had an approval for methylphenidate for narcolepsy prior to 1 April 2008) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the treatment remains appropriate and the patient is benefiting from treatment. Renewal — (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 Applicant is a paediatrician or psychiatrist; or 2.2 Both: 2.2.1 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient; and 2.2.2 Provide name of the recommending specialist. Note: If the patient had an approval for methylphenidate for ADHD prior to 1 April 2008 the applicant is required to submit a fresh initial application in the first instance, not a renewal application. Please phone the Contact Centre on 0800 243 666 for clarification if needed. Renewal — (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment. Note: If the patient had an approval for methylphenidate for ADHD in patients under 5 prior to 1 April 2008 the applicant is required to submit a fresh initial application in the first instance, not a renewal application. Please phone the Contact Centre on 0800 243 666 for clarification if needed. Renewal — (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the treatment remains appropriate and the patient is benefiting from treatment. Note: If the patient had an approval for methylphenidate for narcolepsy prior to 1 April 2008 the applicant is required to submit a fresh initial application in the first instance, not a renewal application. Please phone the Contact Centre on 0800 243 666 for clarification if needed. 142 NICOTINE Nicotine will not be funded Close Control in amounts less than 4 weeks of treatment. a) Maximum of 768 piece per prescription b) Maximum of 384 piece per dispensing c) For the avoidance of doubt Nicotine will not be funded Close Control in amounts less than 4 weeks. d) The maximum of 384 piece per dispensing cannot be waived via Access Exemption Criteria. Gum 2 mg (Classic) ............................................................... 14.97 96 ✔ Habitrol Gum 2 mg (Fruit) .................................................................... 14.97 96 OP ✔ Habitrol Gum 2 mg (Mint) .................................................................... 14.97 96 OP ✔ Habitrol Gum 4 mg (Classic) ............................................................... 20.02 96 ✔ Habitrol Gum 4 mg (Fruit) .................................................................... 20.02 96 OP ✔ Habitrol Gum 4 mg (Mint) .................................................................... 20.02 96 OP ✔ Habitrol NICOTINE Nicotine will not be funded Close Control in amounts less than 4 weeks of treatment. a) Maximum of 432 loz per prescription b) Maximum of 216 loz per dispensing c) For the avoidance of doubt Nicotine will not be funded Close Control in amounts less than 4 weeks. d) The maximum of 216 loz per dispensing cannot be waived via Access Exemption Criteria. Lozenge 1 mg ........................................................................ 11.08 36 OP ✔ Habitrol Lozenge 2 mg ........................................................................ 11.08 36 OP ✔ Habitrol

142

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 January 2011 (continued)

142 NICOTINE Nicotine will not be funded Close Control in amounts less than 4 weeks of treatment. a) Maximum of 56 patch per prescription b) Maximum of 28 patch per dispensing c) For the avoidance of doubt Nicotine will not be funded Close Control in amounts less than 4 weeks. d) The maximum of 28 patch per dispensing cannot be waived via Access Exemption Criteria. Patch 7 mg ............................................................................ 10.53 7 OP ✔ Habitrol Patch 14 mg .......................................................................... 11.63 7 OP ✔ Habitrol Patch 21 mg .......................................................................... 12.32 7 OP ✔ Habitrol MITOMYCIN C – PCT only – Specialist Inj 5 mg ................................................................................. 72.75 TRETINOIN Cap 10 mg – PCT – Retail pharmacy-Specialist ................... 435.90 AZATHIOPRINE – Retail pharmacy-Specialist ❋ Tab 50 mg – Brand switch fee payable................................... 18.45 IPRATROPIUM BROMIDE Nebuliser soln, 250 µg per ml, 1 ml – Up to 40 neb available on a PSO – Brand switch fee payable ................................... 3.79 Nebuliser soln, 250 µg per ml, 2 ml – Up to 40 neb available ....... on a PSO – Brand switch fee payable ................................... 4.06 1 100 100 ✔ Arrow S29 ✔ Vesanoid ✔ Imuprine

149 150 156 163

20 20

✔ Univent ✔ Univent

172

EXTEMPORANEOUSLY COMPOUNDED PRODUCTS & GALENICALS Dermatological base: The products listed in the Barrier creams and Emollients section and the Topical Corticosteroids-Plain section of the Pharmaceutical Schedule are classified as dermatological bases for the purposes of extemporaneous compounding and are the bases to which the dermatological galenicals can be added. Also the dermatological bases in the Barrier Creams and Emollients section of the Pharmaceutical Schedule can be used for diluting proprietary Topical Corticosteroid-Plain preparations. The following products are dermatological bases: • Aqueous cream • Cetomacrogol cream BP • Collodion flexible • Emulsifying ointment BP • Glycerol with paraffin and cetyl alcohol lotion • Hydrocortisone with wool fat and mineral oil lotion • Oil in water emulsion • Oily cream • Urea cream 10% • White soft paraffin • Wool fat with mineral oil lotion • Zinc cream BP • Zinc and castor oil ointment BP • Proprietary Topical Corticosteroid-Plain preparations

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer’s Price

Effective 1 January 2011

37 VITAMINS ( subsidy) ❋ Tab (BPC cap strength) ............................................................ 8.00 (14.80) CAPTOPRIL ( subsidy) ❋ Tab 12.5 mg .......................................................................... 10.00 (10.40) ❋ Tab 25 mg ............................................................................. 12.00 (13.40) ❋ Tab 50 mg ............................................................................. 17.50 (19.00) 1,000 Healtheries Multivitamin tablets 500 Apo-Captopril 500 Apo-Captopril 500 Apo-Captopril

94 147

RALTEGRAVIR POTASSIUM – Special Authority see SA1025 – Retail pharmacy ( subsidy) Tab 400 mg ...................................................................... 1,090.00 60 ✔ Isentress METHOTREXATE ( subsidy) ❋ Inj 1 mg for ECP – PCT only – Specialist ................................... 0.10 1 mg ✔ Baxter

Changes to Sole Subsidised Supply

Effective 1 January 2011

For the list of new Sole Subsidised Supply products effective 1 January 2011 refer to the bold entries in the cumulative Sole Subsidised Supply table pages 8-16.

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Delisted Items

Effective 1 January 2011

25 SODIUM ALGINATE ❋ Oral liq 500 mg with sodium bicarbonate 267 mg per 10 ml (aniseed) .................................................................................. 1.50 (8.64) ZINC OXIDE Oint zinc oxide with balsam peru ............................................... 4.50 (6.67) Suppos zinc oxide with balsam peru ......................................... 4.47 (6.49)

500 ml Gaviscon 50 g OP Anusol 12 Anusol

SODIUM CITRATE WITH SODIUM LAURYL SULPHOACETATE – Only on a prescription Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml .............................................................................. 6.00 12 (7.30) ASCORBIC ACID a) No more than 100 mg per dose b) Only on a prescription ❋ Tab 100 mg ........................................................................... 13.80 (17.25) MULTIVITAMINS – Special Authority see SA1036 – Retail pharmacy Powder .................................................................................. 36.00 Note – Paediatric Seravit powder 200 g OP remains subsidised. TERAZOSIN HYDROCHLORIDE ❋ Tab 1 mg ................................................................................. 1.50 (2.50) ❋ Tab 7 × 1 mg and 7 × 2 mg ................................................... 0.74 ❋ Tab 2 mg ............................................................................... 14.29 (23.30) ❋ Tab 5 mg ............................................................................... 17.86 (29.00) INDAPAMIDE ❋ Tab 2.5 mg .............................................................................. 3.25 CICLOPIROXOLAMINE a) Only on a prescription b) Not in combination Crm 1% .................................................................................... 1.00 (12.82)

Microlax

500 Apo-Ascorbic Acid 100 g OP ✔ Paediatric Seravit

28 14 OP 500 500 Apo-Terazosin 100 ✔ Napamide Apo-Terazosin ✔ Hytrin Starter Pack Apo-Terazosin

54 58

20 g OP Batrafen

DIPHEMANIL METHYLSULPHATE – Subsidy by endorsement Only if prescribed for an amputee with an artificial limb, or for a paraplegic patient and the prescription endorsed accordingly. Powder 2% ............................................................................... 6.81 50 g OP (13.54) Prantal

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Delisted Items - effective 1 January 2011 (continued)

62 GLYCEROL WITH PARAFFIN AND CETYL ALCOHOL – Only on a prescription ❋ Lotn 5% with paraffin liq 5% and cetyl alcohol 2% ..................... 1.40 250 ml (8.10) SODIUM HYPOCHLORITE – Subsidy by endorsement Only if prescribed for a dialysis patient and the prescription is endorsed accordingly. ❋ Soln ......................................................................................... 2.71 2,500 ml ZINC Crm BP .................................................................................... 6.55 (12.00) OILY CREAM ❋ Crm BP .................................................................................... 2.80 (13.60) (15.40) MALATHION Liq 0.5% ................................................................................... 3.79 (4.99) TAR WITH CADE OIL Bath emul 7.5% coal tar, 2.5% cade oil, 7.5% compound .......... 9.70 (29.60) HYDROGEN PEROXIDE ❋ Soln 20 vol – Maximum of 500 ml per prescription .................... 0.63 (2.35) 3.13 (7.00) APPLICATOR When ordered with a spermicide. ❋ Applicator – Up to 1 dev available on a PSO ............................... 4.34 NONOXYNOL-9 Jelly 2% – Up to 108 g available on a PSO ............................... 10.95 DIAPHRAGM – Up to 1 dev available on a PSO One of each size is permitted on a PSO. ❋ 55 mm ................................................................................... 42.90 ❋ 60 mm ................................................................................... 42.90 ❋ 65 mm ❋ 70 mm ❋ 75 mm ❋ 80 mm ❋ 85 mm ................................................................................... 42.90 ................................................................................... 42.90 ................................................................................... 42.90 ................................................................................... 42.90 ................................................................................... 42.90 500 g PSM 500 g David Craig PSM 200 ml OP Derbac-M 350 ml Polytar Emollient 100 ml PSM 500 ml PSM

✔ Janola

1 108 g OP

✔ Ortho ✔ Gynol II

68 69

1 1 1 1 1 1 1 1

❋ 90 mm ................................................................................... 42.90

✔ Ortho Coil ✔ Ortho All-flex ✔ Ortho Coil ✔ Ortho Coil ✔ Ortho Coil ✔ Ortho Coil ✔ Ortho Coil ✔ Ortho All-flex ✔ Ortho Coil ✔ Ortho All-flex ✔ Ortho Coil

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Delisted Items - effective 1 January 2011 (continued)

82 CEFTRIAXONE SODIUM – Subsidy by endorsement a) Up to 5 inj available on a PSO b) Subsidised only if prescribed for a dialysis or cystic fibrosis patient, or the treatment of confirmed ciprofloxacin-resistant gonorrhoea, or the treatment of suspected meningitis in patients who have a known allergy to penicillin, and the prescription or PSO is endorsed accordingly. Inj 1 g ...................................................................................... 2.10 1 (5.40) AFT INFLUENZA VACCINE – Hospital pharmacy [Xpharm] Inj ............................................................................................ 9.00 90.00 1 10 ✔ Fluvax ✔ Influvac ✔ Vaxigrip

142

NICOTINE a) Maximum of 768 piece per prescription b) Maximum of 384 piece per dispensing c) For the avoidance of doubt Nicotine will not be funded Close Control in amounts less than 4 weeks. d) The maximum of 384 piece per dispensing cannot be waived via Access Exemption Criteria. Gum 2 mg (Fruit) .................................................................... 23.41 96 OP ✔ Nicotinell Gum 2 mg (Mint) .................................................................... 23.41 96 OP ✔ Nicotinell Gum 4 mg (Fruit) .................................................................... 23.41 96 OP ✔ Nicotinell Gum 4 mg (Mint) .................................................................... 23.41 96 OP ✔ Nicotinell AZATHIOPRINE – Retail pharmacy-Specialist ❋ Tab 50 mg ............................................................................. 18.45 (34.90) IPRATROPIUM BROMIDE Nebuliser soln, 250 µg per ml, 1 ml – Up to 40 neb available on a PSO ................................................................................... 3.79 Nebuliser soln, 250 µg per ml, 2 ml – Up to 40 neb available on a PSO ................................................................................... 4.06 100 ✔ Azamun Imuran

156

163

20 20

✔ Ipratropium Steri-Neb ✔ Ipratropium Steri-Neb

186

PAEDIATRIC ENTERAL FEED 1.5KCAL/ML – Special Authority see SA0896 – Hospital pharmacy [HP3] Liquid ....................................................................................... 1.60 200 ml OP ✔ Nutrini Energy RTH Note – Nutrini Energy RTH liquid 500 ml OP remains subsidised. PAEDIATRIC ENTERAL FEED 1KCAL/ML – Special Authority see SA0896 – Hospital pharmacy [HP3] Liquid ....................................................................................... 1.07 200 ml OP ✔ Nutrini RTH Note – Nutrini RTH liquid 500 ml OP remains subsidised. ENTERAL FEED WITH FIBRE 1.5KCAL/ML – Special Authority see SA0702 – Hospital pharmacy [HP3] Liquid ....................................................................................... 1.75 250 ml OP ✔ Isosource 1.5 ORAL FEED 1.5KCAL/ML – Special Authority see SA0702 – Hospital pharmacy [HP3] Liquid (chocolate) .................................................................... 1.33 237 ml OP ✔ Resource Plus AMINOACID FORMULA WITH MINERALS WITHOUT PHENYLALANINE – Special Authority see SA0962 – Retail pharmacy – See prescribing guideline Powder .................................................................................. 58.44 250 g OP ✔ Metabolic Mineral Mixture Note – Metabolic Mineral Mixture powder 100 g OP remains subsidised. ❋ Three months or six months, as applicable, dispensed all-at-once

186

190 191 196

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Items to be Delisted

Effective 1 February 2011

41 CLOPIDOGREL Tab 75 mg ............................................................................... 5.05 28 Note – the delisting of Apo-Clopidogrel tab 75 mg, 28 tab pack, has been revoked. ✔ Apo-Clopidogrel

Effective 1 April 2011

37 VITAMINS ❋ Tab (BPC cap strength) ............................................................ 8.00 (14.80) CAPTOPRIL ❋ Tab 12.5 mg .......................................................................... 10.00 (10.40) ❋ Tab 25 mg ............................................................................. 12.00 (13.40) ❋ Tab 50 mg ............................................................................. 17.50 (19.00) PHARMACY SERVICES – May only be claimed once per patient. ❋ Brand switch fee........................................................................ 0.01 The Pharmacode for BSF Imuprine is 2377829 ❋ Brand switch fee........................................................................ 0.01 The Pharmacode for BSF Dapa-Tabs is 2377837 ❋ Brand switch fee........................................................................ 0.01 The Pharmacode for BSF Univent is 2377845 ❋ Brand switch fee........................................................................ 0.01 The Pharmacode for BSF Arrow Terazosin is 2377853 1,000 Healtheries Multivitamin tablets 500 Apo-Captopril 500 Apo-Captopril 500 Apo-Captopril 1 fee 1 fee 1 fee 1 fee ✔ BSF Imuprine ✔ BSF Dapa-Tabs ✔ BSF Univent ✔ BSF Arrow Terazosin

171

Effective 1 July 2011

64 116 118 POVIDONE IODINE Antiseptic soln 10% ................................................................ 51.06 LIGNOCAINE HYDROCHLORIDE Inj 0.5%, 5 ml – Up to 5 inj available on a PSO ......................... 44.10 MORPHINE SULPHATE a) Only on a controlled drug form b) No patient co-payment payable Cap long-acting 200 mg ......................................................... 17.00 4,500 ml 50 ✔ Betadine ✔ Xylocaine

✔ m-Eslon

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Section H page ref

Price (ex man. excl. GST) $ Per

Brand or Generic Manufacturer

Section H changes to Part II

Effective 1 January 2011

20 BUPIVACAINE HYDROCHLORIDE Inf 0.125%, 100 ml theatre pack ........................................... 109.39 5 Marcain Inf 0.125%, 200 ml theatre pack ........................................... 146.23 5 Marcain Inj 0.375%, 20 ml theatre pack ............................................... 56.20 5 Marcain Note – Marcain inf 0.125%, 100 ml and 200 ml theatre packs, and inj 0.375%, 20 ml theatre pack, delisted 1 January 2011 LACTULOSE Oral liq 10 g per 15 ml – 1% DV Mar-11 to 2013....................... 7.68 Note – Duphalac oral liq 10 g per 15 ml to be delisted 1 March 2011 LIGNOCAINE HYDROCHLORIDE Inj 0.5%, 5 ml ......................................................................... 44.10 Note – Xylocaine inj 0.5%, 5 ml delisted 1 January 2011 MORPHINE SULPHATE Cap long-acting 200 mg .......................................................... 17.00 Note: m-Eslon cap long-acting 200 mg to be delisted 1 March 2011 NICOTINE (new listings) Gum 2 mg (classic)................................................................. 14.97 Gum 4 mg (classic)................................................................. 20.02 NICOTINE (expiry of HSS) Note: Nicotrol and Nicorette patches are DV Pharmaceuticals. Patch 7 mg – 10% DV Apr-08 to 31 Dec 2010 ........................ 10.53 Patch 14 mg – 10% DV Apr-08 to 31 Dec 2010 ...................... 11.63 Patch 21 mg – 10% DV Apr-08 to 31 Dec 2010 ...................... 12.32 Lozenge 1 mg – 10% DV Apr-08 to 31 Dec 2010 .................... 11.08 Lozenge 2 mg – 10% DV Apr-08 to 31 Dec 2010 .................... 11.08 Gum 2 mg (fruit) – 10% DV Apr-08 to 31 Dec 2010 ................. 14.97 Gum 2 mg (mint) – 10% DV Apr-08 to 31 Dec 2010 ............... 14.97 Gum 4 mg (fruit) – 10% DV Apr-08 to 31 Dec 2010 ................. 20.02 Gum 4 mg (mint) – 10% DV Apr-08 to 31 Dec 2010 ............... 20.02 RALTEGRAVIR POTASSIUM ( price) Tab 400 mg ...................................................................... 1,090.00 ROCURONIUM BROMIDE Inj 10 mg per ml, 5 ml - 1% DV Mar-11 to 2012...................... 85.00 1,000 ml Laevolac

Xylocaine

m-Eslon

96 96

Habitrol Habitrol

7 7 7 36 36 96 96 96 96 60 10

Habitrol Habitrol Habitrol Habitrol Habitrol Habitrol Habitrol Habitrol Habitrol Isentress Arrow-Rocuronium

51 53 54

ROPIVACAINE HYDROCHLORIDE Inj 2 mg per ml, 10 ml ............................................................ 19.75 5 Naropin Inj 10 mg per ml, 20 ml .......................................................... 74.20 5 Naropin Note – Naropin inj 2 mg per ml, 10 ml, and inj 10 mg per ml, 20 ml, delisted 1 January 2011

Products with Hospital Supply Status (HSS) are in bold. Expiry date of HSS period is 30 June of the year indicated unless otherwise stated

Section H page ref

Price (ex man. excl. GST) $ Per

Brand or Generic Manufacturer

Section H changes Part II - effective 1 January 2011 (continued)

55 SODIUM CHLORIDE Inj 0.9%, 5 ml ......................................................................... 10.85 Inj 0.9%, 10 ml ....................................................................... 11.50 ZINC AND CASTOR OIL ( price) Ointment .................................................................................. 1.29 50 50 20 g Multichem Multichem Orion

Effective 1 December 2010

21 CALCIUM FOLINATE (extension of HSS) Inj 50 mg – 1% DV Sep-08 to 2014 ....................................... 24.50 Inj 100 mg – 1% DV Sep-08 to 2014 ....................................... 9.75 Inj 300 mg – 1% DV Sep-08 to 2014 ..................................... 30.00 Inj 1 g – 1% DV Sep-08 to 2014 ( price)................................ 90.00 22 CARBOPLATIN ( price) Inj 10 mg per ml, 45 ml – 1% DV Dec-09 to 2012 ................... 50.00 Inj 10 mg per ml, 100 ml – 1% DV Dec-09 to 2012 ............... 105.00 5 1 1 1 Calcium Folinate Ebewe Calcium Folinate Ebewe Calcium Folinate Ebewe Calcium Folinate Ebewe Carboplatin Ebewe Carboplatin Ebewe

1 1

DOPAMINE HYDROCHLORIDE Inj 40 mg per ml, 5 ml – 1% DV Feb-11 to 2012 ..................... 82.08 10 Max Health Note – Mayne’s brand of dopamine hydrochloride inj 40 mg per ml, 5 ml to be delisted 1 February 2011. DOXORUBICIN (addition of HSS) Inj 10 mg – 1% DV Feb-11 to 2012 ( price) ........................... 10.00 Inj 50 mg – 1% DV Feb-11 to 2012 ( price) ........................... 40.00 Inj 100 mg – 1% DV Feb-11 to 2012 ( price) ......................... 80.00 Inj 200 mg – 1% DV Feb-11 to 2012 ( price) ....................... 150.00 EPIRUBICIN ( price) Inj 2 mg per ml, 50 ml – 1% DV Oct-09 to 2012 .................... 125.00 Inj 2 mg per ml, 100 ml – 1% DV Oct-09 to 2012 .................. 210.00 ESCITALOPRAM Tab 10 mg – 1% DV Feb-11 to 2013 ......................................... 2.65 Tab 20 mg – 1% DV Feb-11 to 2013 ......................................... 4.20 GEMFIBROZIL Tab 600 mg – 1% DV Feb-11 to 2013 ..................................... 14.00 GLYCERIN WITH SUCROSE Suspension ............................................................................. 38.00 GLYCERIN WITH SODIUM SACCHARIN Suspension ............................................................................. 38.00 1 1 1 1 1 1 28 28 60 473 ml 473 ml Doxorubicin Ebewe Doxorubicin Ebewe Doxorubicin Ebewe Doxorubicin Ebewe Epirubicin Ebewe Epirubicin Ebewe Loxalate Loxalate Lipazil Ora-Sweet Ora-Sweet SF

33 34 34

Products with Hospital Supply Status (HSS) are in bold. Expiry date of HSS period is 30 June of the year indicated unless otherwise stated

Section H page ref

Price (ex man. excl. GST) $ Per

Brand or Generic Manufacturer

Section H changes Part II - effective 1 December 2010 (continued)

38 ITRACONAZOLE Cap 100 mg – 1% DV Feb-11 to 2013 ...................................... 4.25 Note – Sporanox cap 100 mg to be delisted 1 February 2011. ISOSORBIDE MONONITRATE ( price) Tab long-acting 60 mg ............................................................. 3.94 LABETALOL ( price) Tab 50 mg ............................................................................... 8.23 Tab 100 mg ........................................................................... 10.06 Tab 200 mg ........................................................................... 17.55 LABETALOL Tab 400 mg ........................................................................... 34.44 Note – Hybloc tab 400 mg to be delisted 1 February 2011. METHOTREXATE ( price and extension of HSS) Inj 100 mg per ml, 10 ml – 1% DV Nov-08 to 2014 ................. 25.00 Inj 100 mg per ml, 50 ml – 1% DV Nov-08 to 2014 ............... 125.00 METHYLCELLULOSE Suspension ............................................................................. 38.00 METHYLCELLULOSE WITH GLYCERIN AND SUCROSE Suspension ............................................................................. 38.00 METHYLCELLULOSE WITH GLYCERIN AND SODIUM SACCHARIN Suspension ............................................................................. 38.00 MOXIFLOXACIN Tab 400 mg ............................................................................ 52.00 Soln for inf 1.6 mg per ml, 250 ml ........................................... 70.00 NIFEDIPINE ( price) Tab long-acting 30 mg ............................................................. 8.56 Tab long-acting 60 mg ........................................................... 12.28 OXALIPLATIN ( price) Inj 50 mg – 1% DV Jan-10 to 2012 ......................................... 55.00 Inj 100 mg – 1% DV Jan-10 to 2012 ..................................... 110.00 PACLITAXEL ( price and extension of HSS) Inj 30 mg – 1% DV Oct-08 to 2014 ...................................... 137.50 Inj 100 mg – 1% DV Oct-08 to 2014 ....................................... 91.67 Inj 150 mg – 1% DV Oct-08 to 2014 ..................................... 137.50 Inj 300 mg – 1% DV Oct-08 to 2014 ..................................... 275.00 Inj 600 mg – 1% DV Oct-08 to 2014 ..................................... 550.00 PROPRANOLOL ( price) Cap long-acting 160 mg ......................................................... 16.06 15 Itrazole

38 39

90 100 100 100 100

Duride Hybloc Hybloc Hybloc Hybloc

1 1 473 ml 473 ml 473 ml 5 1 30 30 1 1 5 1 1 1 1 100

Methotrexate Ebewe Methotrexate Ebewe Ora-Plus Ora-Blend Ora-Blend SF Avelox Avelox IV 400 Adefin XL Adefin XL Oxaliplatin Ebewe Oxaliplatin Ebewe Paclitaxel Ebewe Paclitaxel Ebewe Paclitaxel Ebewe Paclitaxel Ebewe Paclitaxel Ebewe Cardinol LA

43 43 43 45

Products with Hospital Supply Status (HSS) are in bold. Expiry date of HSS period is 30 June of the year indicated unless otherwise stated

Section H page ref

Price (ex man. excl. GST) $ Per

Brand or Generic Manufacturer

Section H changes Part II - effective 1 December 2010 (continued)

53 RIVAROXABAN Tab 10 mg ............................................................................ 153.00 306.00 SERTRALINE Tab 50 mg – 1% DV Feb-11 to 2013......................................... 5.40 Tab 100 mg – 1% DV Feb-11 to 2013 ....................................... 9.60 SODIUM CHLORIDE Inf 0.9% ................................................................................... 1.70 1.71 VERAPAMIL HYDROCHLORIDE Tab long-acting 120 mg ......................................................... 15.20 15 30 90 90 500 ml 1,000 ml 250 Xarelto Xarelto Arrow-Sertraline Arrow-Sertraline Freeflex Freeflex Verpamil SR

Products with Hospital Supply Status (HSS) are in bold. Expiry date of HSS period is 30 June of the year indicated unless otherwise stated

Index

Pharmaceuticals and brands A Adefin XL ........................................................... 33 Aminoacid formula with minerals without phenylalanine .................................................. 29 Anusol ............................................................... 27 Apo-Ascorbic Acid ............................................. 27 Apo-Bromocriptine ............................................. 19 Apo-Captopril ............................................... 26, 30 Apo-Clopidogrel ................................................. 30 Apo-Terazosin.................................................... 27 Applicator .......................................................... 28 Arrow-Rocuronium ............................................ 31 Arrow-Sertraline ................................................. 34 Ascorbic acid ..................................................... 27 Avelox.......................................................... 19, 33 Avelox IV 400..................................................... 33 Azamun ............................................................. 29 Azathioprine ................................................. 25, 29 B Batrafen ............................................................. 27 Betadine............................................................. 30 Bromocriptine mesylate...................................... 19 BSF Arrow Terazosin .................................... 18, 30 BSF Dapa-Tabs ............................................ 18, 30 BSF Imuprine ............................................... 18, 30 BSF Univent ................................................. 18, 30 Bupivacaine hydrochloride.................................. 31 C Calcium folinate ................................................. 32 Calcium Folinate Ebewe...................................... 32 Captopril ...................................................... 26, 30 Carboplatin ........................................................ 32 Carboplatin Ebewe ............................................. 32 Cardinol LA ........................................................ 33 Ceftriaxone sodium ............................................ 29 Ciclopiroxolamine............................................... 27 Clopidogrel ........................................................ 30 D Dapa-Tabs ......................................................... 19 Dapsone ............................................................ 19 Derbac-M .......................................................... 28 Dexamphetamine sulphate.................................. 21 Diaphragm ......................................................... 28 Diphemanil methylsulphate ................................. 27 Dopamine hydrochloride .................................... 32 Doxorubicin ....................................................... 32 Doxorubicin Ebewe ............................................ 32 Duride ................................................................ 33 E Enteral feed with fibre 1.5kcal/ml ........................ 29 Epirubicin........................................................... 32 Epirubicin Ebewe................................................ 32 Escitalopram ...................................................... 32 F Fluarix ................................................................ 17 Fluvax .......................................................... 17, 29 Freeflex .............................................................. 34 G Gabapentin ........................................................ 19 Gaviscon ........................................................... 27 Gemfibrozil ........................................................ 32 Glycerin with sodium saccharin .......................... 32 Glycerin with sucrose ......................................... 32 Glycerol with paraffin and cetyl alcohol ............... 28 Gynol II .............................................................. 28 H Habitrol ............................................ 18, 24, 25, 31 Healtheries Multi-vitamin tablets ................... 26, 30 Hybloc ............................................................... 33 Hydrogen peroxide ............................................. 28 Hytrin Starter Pack ............................................. 27 I Imuprine ............................................................ 25 Imuran ............................................................... 29 Influenza vaccine.......................................... 17, 29 Influvac .............................................................. 29 Indapamide .................................................. 19, 27 Ipratropium bromide ..................................... 25, 29 Ipratropium Steri-Neb ......................................... 29 Isentress ...................................................... 26, 31 Isosorbide mononitrate....................................... 33 Isosource 1.5..................................................... 29 Itraconazole ....................................................... 33 Itrazole ............................................................... 33 J Janola ................................................................ 28 L Labetalol ............................................................ 33 Lactulose ..................................................... 17, 31 Laevolac ...................................................... 17, 31 Lignocaine hydrochloride ............................. 30, 31 Lipazil ................................................................ 32 Loxalate ............................................................. 32 M m-Eslon ....................................................... 30, 31 Malathion ........................................................... 28 Marcain ............................................................. 31 Metabolic Mineral Mixture................................... 29 Methylcellulose .................................................. 33 Methylcellulose with glycerin and sodium saccharin............................................ 33 Methylcellulose with glycerin and sucrose .......... 33 Methotrexate ................................................ 26, 33 Methotrexate Ebewe ........................................... 33

Index

Pharmaceuticals and brands Methylphenidate hydrochloride ........................... 23 Microlax ............................................................. 27 Mitomycin C ...................................................... 25 Morphine sulphate........................................ 30, 31 Moxifloxacin................................................. 19, 33 Multivitamins ..................................................... 27 N Napamide .......................................................... 27 Naropin .............................................................. 31 Nicotine ..................................... 18, 24, 25, 29, 31 Nicotinell ............................................................ 29 Nifedipine........................................................... 33 Nonoxynol-9 ...................................................... 28 Nupentin ............................................................ 19 Nutrini Energy RTH ............................................. 29 Nutrini RTH ........................................................ 29 O Oily cream ......................................................... 28 Ora-Blend .......................................................... 33 Ora-Blend SF...................................................... 33 Oral feed 1.5kcal/ml ........................................... 29 Ora-Plus ............................................................ 33 Ora-Sweet.......................................................... 32 Ora-Sweet SF ..................................................... 32 Ortho ................................................................. 28 Ortho All-flex ...................................................... 28 Ortho Coil .......................................................... 28 Oxaliplatin Ebewe ............................................... 33 Oxaliplatin .......................................................... 33 P Paclitaxel ........................................................... 33 Paclitaxel Ebewe ................................................ 33 Paediatric enteral feed 1.5kcal/ml ....................... 29 Paediatric enteral feed 1kcal/ml .......................... 29 Paediatric Seravit ............................................... 27 Pharmacy services....................................... 18, 30 Polytar Emollient ................................................ 28 Povidone iodine ................................................. 30 Prantal ............................................................... 27 Propranolol ........................................................ 33 Q QV ..................................................................... 28 R Raltegravir potassium................................... 26, 31 Resource Plus.................................................... 29 Ritalin ................................................................ 23 Ritalin SR ........................................................... 23 Rivaroxaban ....................................................... 34 Rocuronium bromide ......................................... 31 Ropivacaine hydrochloride ................................. 31 Rubifen .............................................................. 23 Rubifen SR ........................................................ 23 S Sabril ................................................................. 20 Sertraline ........................................................... 34 Sodium alginate ................................................. 27 Sodium chloride ..................................... 17, 32, 34 Sodium citrate with sodium lauryl sulphoacetate . 27 Sodium hypochlorite .......................................... 28 T Tar with cade oil................................................. 28 Terazosin hydrochloride ............................... 19, 27 Tretinoin ............................................................ 25 U Univent .............................................................. 25 V Vaxigrip ............................................................. 29 Verapamil hydrochloride ..................................... 34 Verpamil SR ....................................................... 34 Vesanoid............................................................ 25 Vigabatrin .......................................................... 20 Vitamins ...................................................... 26, 30 X Xarelto ............................................................... 34 Xylocaine ..................................................... 30, 31 Z Zinc ................................................................... 28 Zinc and castor oil .............................................. 32 Zinc oxide .......................................................... 27

Pharmaceutical Management Agency Level 9, 40 Mercer Street, PO Box 10-254, Wellington 6143, New Zealand Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - www.pharmac.govt.nz Freephone Information line (9am-5pm weekdays) 0800 66 00 50 ISSN 1172-9376 (Print) ISSN 1179-3686 (Online)

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the Update.

If Undelivered, Return To: PO Box 10-254, Wellington 6143, New Zealand

Metadata

Title

Schedule Update - effective 1 January 2011

Abstract

Pharmaceutical Management Agency Update New Zealand Pharmaceutical Schedule Effective 1 January 2011 Section H cumulative for December 2010 and January 2011 Contents Summary of PHARMAC decisions effective 1 January 2011 … 3 Pharmacy Brand Switch payments …. 5 Nicotine –…

Page 1

Note

This text has been extracted from the source PDF document.

Also available as plain text.

Please contact webmaster to discuss alternative format options.